| The Company’s concerted focus on the semi-acute therapy is the crux of the Lupin division, which has enabled the Company to attain market leadership in the Anti-TB segment of IPM. In a Rs.3,162
mn Anti-TB market, Lupin commands 48% of the market share. As market leaders in this space, Lupin has embarked on an effort which would redefine the treatment guidelines based on conditions existing in India under the aegis of RIETT-Redefining Indian Expertise Based Tuberculosis Treatment.
Key Products : Lupin Pharma
|
Product |
Therapeutic segment
|
Product Rank in the relevant segment |
|
R-Cinex |
Anti-TB |
1 |
|
AKT |
Anti-TB |
1 |
|
Akurit |
Anti-TB |
1 |
|
R-CIN |
Anti-TB |
1 |
|
G-CIN |
Gemifloxacin |
1 |
|
Combutol |
Ethambutol & Comb. |
1 |
|
Pyzina |
Pyrazinamide Plain |
2 |
| 
